Intrinsically disordered proteins (IDPs) are emerging as attractive drug targets by virtue of their prevalence in various diseases including cancer. Drug development targeting IDPs is challenging because they have dynamical structure features and conventional drug design is not applicable. NUPR1 is an IDP playing an important role in pancreatic cancer. We previously reported that Trifluoperazine (TFP), an antipsychotic agent, was capable of binding to NUPR1 and inhibiting tumors growth. Unfortunately, TFP showed strong central nervous system side-effects. In this work, we undertook a multidisciplinary approach to optimize TFP, based on the synergy of computer modeling, chemical synthesis, and a variety of biophysical, biochemical and biological evaluations. A family of TFP-derived compounds was produced and the most active one, named ZZW-115, showed a dose-dependent tumor regression with no neurological effects and induced cell death mainly by necroptosis. This study opens a new perspective for drug development against IDPs, demonstrating the possibility of successful ligand-based drug design for such challenging targets.
Introduction NUPR1 was first described as being activated in the exocrine pancreas in response to the cellular injury induced by pancreatitis (1) . Subsequently, the inducible expression of Nupr1 was discovered to be a common response to many stresses (2, 3) , including minimal ones (4) in almost all cells. Moreover, NUPR1 was found to be overexpressed in some, if not all, cancer tissues compared to healthy tissue, making NUPR1 an excellent target for cancer treatment. From a molecular point of view, NUPR1 binds to DNA in a manner similar to other chromatin proteins (5, 6) for controlling the expression of gene targets (7) . At the cellular level, NUPR1 participates in many cancer-associated processes including cell-cycle regulation, apoptosis (8, 9) , senescence (6) , cell migration and invasion (10) , development of metastasis (11) and DNA repair responses (12) . Indeed, NUPR1 has recently elicited significant attention due to its role in promoting cancer development and progression in the pancreas (7, 13) . Notably, NUPR1-dependent effects also mediate resistance to anticancer drugs (14) (15) (16) . Moreover, we have previously showed that genetic inactivation of Nupr1 antagonizes the growth of pancreatic cancer (10, 17) , and other laboratories have also shown that genetic inactivation of Nupr1 stops the growth of hepatocarcinoma (18) , nonsmall lung cancer (19) , cholangiocarcinoma (20) , glioblastoma (21) , multiple myeloma (22) (23) (24) , and osteosarcoma (25) , thereby supporting a role for this protein as a promising therapeutic target for developing new therapies for cancers.
Structurally, NUPR1 is an intrinsically disordered protein (IDP) with an entirely disordered conformation (5, (26) (27) (28) (29) , and consequently the target-based high throughput screening for drug-selection towards this protein is highly challenging. In fact, drug-targeting IDPs is difficult due to their extremely dynamic nature, typically weak binding affinities with their natural partners, and the fact that many of them have usually several binding hotspots.
Trying to use NUPR1 as a model IDP to be drug-targeted, we recently developed a combination of biophysical, biochemical, bioinformatic and biological approaches for a molecular screening in vitro, in vivo, in silico and in cellulo to select potential drug candidates against NUPR1. To this aim, we had previously followed a bottom-up approach (30) . We have first characterized in vitro the interactions between NUPR1 and the potential ligands by using a collection of 1120 FDA-approved compounds. We have employed a screening method based on fluorescence thermal denaturation (31) , and identified the wellknown antipsychotic agent Trifluoperazine (TFP) and its structurally related Fluphenazine hydrochloride as ligands inducing significant differences in the temperature denaturation profile for NUPR1. Phenotypic assays have been carried out to assess the potential bioactivity of TFP, as selected from biophysical screenings. Cell viability assays in the presence of TFP have led to IC 50 of around 10 µM. Tests of TFP in vivo with human pancreatic cancer cells-derived xenografts implanted into immunocompromised mice have shown a tumor volume increase of only 50% compared to the control, whereas in mice treated with a higher dose of TFP the tumor growth has been rapidly and almost completely stopped (30) .
Therefore, we have previously successfully repurposed TFP as a possible cancer drug for treating pancreatic ductal adenocarcinoma (PDAC). Unfortunately, high doses of TFP also led to neurological effects on treated mice such as strong lethargy and hunched posture.
Although relatively efficient as an anticancer agent, the neurological effects observed in mice preclude the use of TFP in clinics to treat cancers. For this reason, in this work we developed a multidisciplinary approach to improve the compound by, on one hand, increasing its anticancer effect and, on the other hand, reducing its undesirable neurological side-effects. In fact, a rational, in silico ligand-design guided the organic synthesis of TFPderived compounds, which showed a stronger affinity in vitro for NUPR1, as indicated by a combination of spectroscopic and biophysical studies. One of these hit, named ZZW-115, showed a very evident antitumor activity via interacting with NUPR1, therefore being a promising candidate for PDAC treatment, as well as in other cancers. Furthermore, we observed that this compound induced cell death by necroptotic and apoptotic mechanisms, with a concomitant mitochondrial metabolism failure that triggers lower production of ATP and reactive oxygen species (ROS) overproduction. This work also demonstrated how the repurposing of a drug can be used as a starting point to improve the design and the efficiency of better drugs against cancer, even for challenging targets such as IDPs , and constitutes an innovative example of successful ligand-based (as opposed to structurebased) design of an inhibitor for an entirely unfolded protein.
Results

Ligand-based design and synthesis of the Trifluoperazine-derived compounds
Drug design via targeting NUPR1: The first step in the development of TFP-derived compound was to carry out in silico a ligand-based rational design, also known as "indirect" drug design. In brief, starting from the structure of TFP, we defined models of the target regions of NUPR1 that are prone to coordinate this ligand, although in a context of high molecular flexibility. To this aim, molecular dynamics (MD) simulation of NUPR1 was performed, and short fragments of the protein (up to seven amino acid residues) were used as receptors for molecular docking of TFP. These relatively small protein-ligand anchoring locations were completed with docking of additional fragments of NUPR1, and the resulting showed that the phenothiazine and the attached trifluoromethyl group are important for TFP to maintain coordination with the protein, with average binding energy of -7.0 kcal/mol for the parent ligand. The rest of the ligand structure is progressively less critical in anchoring to NUPR1, and may provide entropic more than enthalpic contributions to the binding. On these bases, molecular modifications were explored in the propyl linker between the phenothiazine and piperazine ring, and in the methyl group attached to the latter ( Figure   1B ). Variations in the length of the linker were found to be not significantly effective in improving the docking of TFP-derived compounds, due to a reduction in the enthalpic component of the binding. Thus, this left the methyl group as the most suitable region to modify for obtaining new active analogs of TFP for inhibiting NUPR1, and we focus our synthetic effort on changing this methyl group. Improvements in the binding energies with the methyl group substitution were up to -0.5 kcal/mol, although they depended upon the specific modification and showed a typical uncertainty of the same order of the variation estimated.
Compound synthesis: The structure of the synthesized TFP-derived compounds ZZW-111, ZZW-112, ZZW-115 and ZZW-116 is presented in Figure 1C . All the target compounds can be prepared starting from 2-(trifluoromethyl)-10H-phenothiazine, which was coupled with 1,3-dibromepropane and further various piperazine analogues to afford the TFP analogue bearing different functional groups in the piperazine moiety ( Figure 1C) . Moreover, the hydrochlorides of these compounds (ZZW-119, ZZW-120 and ZZW-124) were also synthesized to obtain the corresponding water-soluble candidates ( Figure 1C) .
Fluorescence, NMR, CD and ITC studies of the candidate compounds
Fluorescence: With the TFP-derived compounds predicted in silico in hand we then screened the selected compounds following a fluorescence-based strategy to identify the hits which could bind to NUPR1: i/ acquisition of the intrinsic fluorescence spectra of NUPR1 (which only contains two Tyr residues) either in the absence or presence of the TFP derivatives; and ii/ acquisition of the fluorescence spectra of the probe ANS (8-anilinonaphtalene-1-sulfonic acid) when NUPR1 was either isolated in solution or in the presence of the compounds. In the two strategies we were trying to monitor whether there were changes in the environment around, respectively, the two Tyr residues in NUPR1, or in the environment around where ANS binds to NUPR1 ( Figure 1D and Figure S1A ). By using both fluorescent approaches we were able to show that i/ the region around Tyr30 and Tyr36 of NUPR1 changed its conformation in the presence of any of the ZZW compounds ( Figure S1A) ; and ii/ ANS fluorescence also varied in the presence of the TFP derivatives, indicating that ANS competes for solvent-exposed hydrophobic patches of NUPR1, with the compounds. Thus, the above results revealed that there was binding of NUPR1 to any of the compounds, and that such binding occurred around the 30s region of the sequence and altered some solventexposed hydrophobic patches of NUPR1.
CD:
We also acquired far-UV circular dichroism (CD) experiments with some selected compounds, ZZW-116 and ZZW-115; the presence of DMSO, used to prepare the stock solutions of the compounds, precluded the acquisition of many of the CD spectra (either that of the isolated compound or in the presence of NUPR1), as it absorbs strongly at short wavelengths. The aim of using CD as a spectroscopic probe is to determine whether NUPR1 modified its secondary structure in the presence of the compounds. The results with ZZW-115 and ZZW-116 ( Figure S1B ) indicate that none of the compounds change the secondary structure of the protein (as it is further confirmed by the NMR results, see below).
NMR:
Once we had spectroscopically determined that there was binding between NUPR1 and the compounds, we aimed to verify whether the NUPR1 binding region was the same as observed for TFP (30 (Figure S1C ), but rather variations in their intensities upon addition of any of them ( Figure S1D ). This indicates that NUPR1 remained disordered upon binding to the compounds and no new secondary or tertiary structures were acquired. The protein residues whose cross-peak intensity was affected upon addition of the ZZW compounds are indicated in Table 1 . When compared to the TFP, all the compounds affected the intensities of the cross-peaks of a similar set of residues, namely those around the 20s region and those at the C terminus of the protein. Besides TFP-derived compounds showing the largest number of protein residues of NUPR1 affected in the binding were ZZW-111 and ZZW-112. Thus, we can conclude that there was binding between the compounds and NUPR1, and that this binding is not unspecific, since only a subset of residues were affected.
Isothermal titration calorimetry (ITC):
The interaction between TFP-derived compounds and (derived from a liver metastasis) and HN14 (classical subtype) cells with compounds ZZW-112, ZZW-116, ZZW-120 and ZZW-124 showed an effect on cell growth which was close to that induced by TFP, whereas treatment with ZZW-111 and ZZW-119 was two to three times more efficient in decreasing cell growth. Remarkably, treatment with ZZW-115 was around ten times more efficient than with TFP ( Figure 2A and Table 2 ). Altogether, these data strongly suggested that: i/ the effect of these TFP-derived compounds seemed to be independent of the subtype of pancreatic cancer cells; ii/ ZZW-115 was the most efficient expression is systematically overexpressed in PDAC cells, but small differences between cell lines were founded. Finally, NUPR1 expression was plotted against the AUC (area under the curve) after ZZW-115-treatment and no significant correlation was found ( Figure 2C) . In this regard, we cannot cluster cell lines in low/high expression or low/high sensibility.
Since resistance to chemotherapy is a common issue that oncologists must face in the treatment of patients with PDAC, we used the MiaPaCa-2 cell line, which has become resistant to the two chemotherapeutic agents oxaliplatin or gemcitabine, to assess whether resistance to them is also conferring resistance to ZZW-115. Remarkably, ZZW-115-treatment of resistant MiaPaCa-2 cells showed the same sensitivity as the parental cells, as demonstrated in Figure 2D . We hence suggest that the antitumor effect of the ZZW-115 is not influenced by the resistance to others drugs and may affect some other intracellular pathways. 
ZZW-115 inhibits the growth pancreatic xenografted tumors in vivo
Because the compound ZZW-115 was the most efficient candidate for treating cancer cells in vitro, we therefore selected it to treat MiaPaCa-2 cells-xenografted mice. We applied a protocol similar to that previously used for validating TFP in vivo (30) . Figure   3C ). In addition, histological analysis of the tumors, after the 30 days of treatment with ZZW-115, showed obvious areas of necrosis as shown in Figure 3F . Furthermore, numerous apoptotic cells were also observed.
We then evaluated the effect of ZZW-115 on the PDX1-Cre; Kras G12D ; Ink4a flox/flox mice model.
This animal model can spontaneously develop an aggressive PDAC that leads to the mice death at the age of 9 to 10 weeks. We started the daily ZZW-115-treatment (5 mg/kg) at week 5 of life and then sacrificed the mice at the end of week 8. Importantly, the pronecrotic effect induced by ZZW-115 was still noticeable after 3 weeks of treatment in PDX1-Cre;Kras G12D ;Ink4a flox/flox mice ( Figure 3F ). The percentage of necrotic area in the tumors was calculated by histological analysis after hematoxilin and eosin (H&E) staining. We found a significant increase of necrosis in ZZW-115-treated mice, from 10% to 43% of the surface area in some tumors, whereas in the PDAC from the untreated mice these areas were in the ranged from 0 to 3.5% ( Figure 3G ). We hence conclude that ZZW-115 could disrupt tumor growth (at low doses) and could reduce tumor size (at high doses) for the xenografted tumors, without obvious neurological side-effects in the mice.
ZZW-115 induces pancreatic cell death by necrosis and apoptosis
Although ZZW-115 treatment kills cancer cells and decreases the size of the xenografted pancreatic cancer tumors, details of its molecular mechanism are unknown. Prompted by our results described above, we measured the necrotic and the apoptotic effects throughout the LDH release and caspase 3/7 activity, respectively, in several pancreatic primary cancer cells. Upon ZZW-115 treatment, we found that LDH release was significantly higher in ZZW- Figure 4A and Figure S2A . Similarly, caspase 3/7 activity was also larger in ZZW-115-treated cells, as showed in Figure 4B and Figure As it is well-known, mitochondrial dynamics is related to the cell death pathways.
115-treated cells than in control ones in a concentration-dependent manner as presented in
Mitochondrial dysfunction, including decreased respiration and oxidative phosphorylation (OXPHOS), metabolic shift towards glycolysis, and increased mitochondrial ROS-formation, leads to the activation of pro-survival or pro-death pathways depending on the stimulus (33) . In this regard, we were interested in understanding whether mitochondrial ROS production was involved in cell death induced by ZZW-115. To answer this question we measured superoxide formation by using MitoSOX labelling and found a significant increase in the ROS formation ( Figure 5E ). Moreover, in the PDAC cell lines panel, ROS production is positively correlated with the cell sensibility, and inversely correlated with the ATP production. Furthermore, to better understand the relation between the cell death and metabolism failure, we performed experiments in ZZW-115-treated MiaPaCa-2 cells, where we measured the ATP content after pretreatment with Z-VAD-FMK or/and Nec-1. Our results, presented in Figure 5F , showed that the ATP content could be restored by inhibiting both necrosis and apoptosis. Accordingly, Nec-1, which showed the most efficient rescue capacity after ZZW-115-treatment, presented also a stronger ability to restore the ATP content. Moreover, Nec-1 pretreatment of ZZW-115-treated cells was able to increase anaerobic glycolysis whereas no improvement was found in the mitochondrial metabolism In this work we described the synthesis and characterization of a novel TFP-derived compound with a strong anticancer effect both in vitro and in vivo, due to its capability of inducing programmed necrosis and apoptosis. Based on a modeled structure of NUPR1 and of the selected fragments of its sequence involved in ligand binding, a collection of compounds was designed and synthesized with the aim of improving the affinity towards the protein target compared to the cognate drug. The biophysical and biochemical analysis of these compounds showed that ZZW-115 was bound to NUPR1 more favorably than TFP ( (40) , in an early attempt to repurpose the drug. However, TFP cannot be used in clinic for treating patients with cancers due to its numerous, undesirable side-effects, at efficient anticancer doses. This is why it is important to use a rational approach to develop new TFP-derived compounds, with little side-effects and higher anticancer activity. On the basis of our previous observation that TFP binds to NUPR1 and blocks its activity (30) leading to anticancer effect in PDAC, we built models of the NUPR1-TFP complex which could give us hints on how to improve the interaction with some novel derivatives. This constitutes an original ligand-based approach to the rational design of drugs against a totally unstructured protein, whereas previous pioneer attempts only included structure-based design against partly-folded IDPs (41) . The capacity of interaction with NUPR1 of such new compounds was biophysically and biochemically validated by using several spectroscopic and biophysical strategies; a stronger interaction with NUPR1 was found in particular for the compound ZZW-115 (Table 1) , which also resulted in an improved anticancer activity both in vitro and in vivo. Noteworthy, and in contrast with TFP treatment, no apparent neurological effect was observed on mice, even at 10 mg/kg dose administrated daily for 30 days.
Inhibition of the NUPR1 activity as an anticancer strategy was evaluated and proven in pancreatic cancer (10, 17) , but also in several other solid and liquid tumors such as hepatocarcinoma (18), non-small lung cancer (19) , cholangiocarcinoma (20) , glioblastoma (21), multiple myeloma (22) (23) (24) , and osteosarcome (25) . These findings indicate that ZZW-115 could be used for treating tumors from different origins with a range of IC 50 from 0.42 μM to 7.75 μM ( Figure 2E) . Thus, we believe that ZZW-115 is a promising agent for treating various cancers due to its effectiveness in targeting NUPR1, since the protein is commonly overexpressed in many cancerous tissues.
The compound ZZW-115 acts at cellular level by promoting programmed necrosis: insights into its cellular functions.
Histological study from both PDAC mice models, xenografts and tumors from PDX1-Cre;Kras G12D ;Ink4a flox/flox mice, demonstrate a strong pro-necrotic effect of ZZW-115 treatment; this effect makes ZZW-115 an extremely original drug candidate. In this regard,
we noted that only a very small number of compounds rely on the capability of inducing necrosis as the main cause of their anticancer activity. For each novel candidate proposed to become an anticancer drug, such as ZZW-115, an essential prerequisite is to understand its mechanism of action. Moreover, understanding the cell death pathways elicited through a potential anticancer drug represents a milestone in preclinical studies. This is why we performed several functional studies to clarify this aspect, and found that treatment with
ZZW-115 of a whole panel of pancreatic cancer cells, as well as other cancer cells, induced in
all cases a programmed cell death mainly by necrosis, but concomitantly also by apoptosis.
In fact, cell rescue was possible by using two distinct cell death inhibitors, i. An important question that needs to be answered is why the cancer cells are sensitive to this strong pro-necrotic compound, whereas normal cells, as observed in mice treated with high doses, up to 10 mg/kg/day during 30 days, do not show evidences of off-target effects. We suggest that this is due to the fact that cancer cells are more reliant on NUPR1-dependent pathways. In fact, we hypothesize that since cancer cells are growing under hypoxia, low contribution of nutrients, mechanic stress and various other constrained conditions, these stress situations activate NUPR1 expression, and therefore NUPR1-dependent mechanisms can help cells to adapt to such environmental conditions. Thus, cancer cells become highly dependent on the NUPR1 activity to live and grow under stress conditions. That is, cancer cells, but not healthy ones, are probably fully dependent on a NUPR1-adaptative mechanism.
It is also interesting to note that after ZZW-115 treatment we found a very remarkable metabolic failure due to a mitochondrial metabolism rupture. This mitochondrial failure was accompanied with an increase of mitochondrial ROS production that raised cell instability and oxidative stress. Following mitochondrial respiration stress, cells shift towards anaerobic glycolytic metabolism to compensate for the lack of ATP (32). This anaerobic shift was observed between 4 and 8 hours after the treatment with ZZW-115 ( Figure 5C ). Glycolysis is a less favorable ATP-producer pathway and cells rapidly consume glycolytic reserves, leading to ATP decrease, and then, to programmed cell death by both necroptosis and apoptosis.
These results are in agreement with the fact that treating pancreatic cells with a siRNA against NUPR1 (34) or with TFP (unpublished data) induces a similar metabolic disruption.
Material and Methods
Computational modeling of a TFP-derived compound
MD simulations of NUPR1 were carried out in the isobaric-isothermal ensemble using the GROMACS simulation package (43) in combination with the force fields AMBER ff99SB-ILDN (44) . The protein was equilibrated in explicit TIP4P-D water (45) starting from an extended conformation, following a protocol previously described (27) . Fragments of the simulated protein structure with a length of 5 or 7 amino acid residues were used as receptors for molecular docking of either TFP or TFP-derived compounds, by using the AutoDock Vina software (46) . The choice of using short fragments of NUPR1 was motivated not only by the necessity of reducing its exceedingly large conformational space, but also by the fact that ligand binding to the protein is dictated by local hydrophobicity spanning up to seven amino acid residues (28, 30) . Furthermore, we have previously proved that molecular docking is sufficiently accurate to reveal the binding locations of drugs to NUPR1 in a blind search (30) .
After docking of the ligand, the complex was considered as is or completed with addition of a second fragment of NUPR1, selected among those that had shown the most favorable affinity for the same ligand in the previous docking calculations. The resulting complexes were equilibrated by 1 ns of MD performed using the GAFF force field (47) for the compounds. Simulation conditions including treatment of the electrostatics and van der Waals interactions, and reference values and coupling times for both the thermostat and barostat, were as formerly reported (27, 29) . After the MD runs, the binding affinity of the compounds was evaluated using the scoring function of AutoDock Vina (46), by performing a re-docking of the ligand in the position occupied within the average structure of the simulated complex.
Synthesis of TFP-derived compounds
The 2-(trifluoromethyl)-10H-phenothiazine (1, 204 mg), 1,3-dibromepropane (0.4 mL) and 
Protein expression and purification
NUPR1 was produced and purified from transformed E. coli grown in LB media as previously described (5) . For the production of and emission spectra were collected from 400 to 600 nm. Slit widths were the same as before.
NMR spectroscopy
The NMR data were acquired at 25°C, pH 4.5 (acetate buffer), on a Bruker Avance DRX-500 spectrometer equipped with a triple-resonance probe and z-gradients. All spectra were referenced to external TSP (48) . The 2D Assignments were taken from those previously reported for NUPR1 (26) . The intensity of the signals from each row in the HSQC spectra was measured by using TopSpin 2.1 and taking into account, as an internal reference, the intensity of the last residue of NUPR1. Only differences in intensity of a particular protein residue between spectra of the complex (NUPR1:compound) and that of isolated NUPR1 were considered significant only larger than 10%.
Far-UV circular dichroism spectroscopy
The far-UV CD experiments were acquired in a Jasco J815 spectropolarimeter (Jasco, Japan) with a thermostated cell holder, and interfaced with a Peltier unit, at 25 °C. The instrument 
Isothermal titration calorimetry (ITC) assays
The binding of the TFP-derived ZZW compounds to NUPR1 was determined with a high sensitivity isothermal titration calorimeter Auto-iTC200 (MicroCal-Malvern Panalytical). 
Cell viability assays
Cell viability after treatment was assessed in cancer cell lines: MiaPaCa-2 and Panc-1 (pancreatic cancer), U87 (glioblastoma), A375 and B16 (melanoma), U2OS and SaOS In an independent group of 6 mice, animals were xenografted and treated with 5 mg/kg of ZZW-115 during 30 days as described above but the tumor growth was followed by an additional 30 days-period without any additional treatment.
Necrosis evaluation
To perform necrosis evaluation of the tumor, formalin-fixed samples were embedded in paraffin and 5-μm sections were stained with hematoxilin and eosin (H&E). Percentage of necrotic area was calculated by the ImageJ program.
CRISPR-Cas9 clones development
Cells were seeded and transfected with 1 µg of NUPR1 double nickase plasmid or double control nickase plasmid (Santa Cruz Biotechnology, Heidelberg Germany), using
Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific, Carlsbad, CA) in each well, following the manufacturer's protocol. Transfected cell selection was performed with puromycin and, after 72 h, single cell colonies were isolated. Complete allelic knockouts were confirmed using Sanger sequencing.
siRNA transfection
Cells were plated at 70% confluence and INTERFERin reagent (Polyplus-transfection) was used to perform siRNA transfections, according to the manufacturer's protocol. Scrambled siRNA that targets no known gene sequence was used as a negative control. Assays were carried out 72 h post-transfection.
LDH assay, ATP production, and caspase-3/7 activity assay
MiaPaCa-2 cells were seeded at a density of 10,000 cells/well in 96-well plates. Cells were allowed to attach overnight and treated the next day for 24 h with different concentrations of ZZW-115. At the end of the experiment, LDH release, ATP production, and caspase-3/7 activity were monitored using CytoTox-ONE (Promega G7890, Madison, WI), CellTiter-Glo (Promega G7571, Madison, WI) and Caspase-Glo 3/7assay (Promega G8091, Madison, WI), respectively. Data were normalized with respect to the cell number.
OXPHOS and glycolitic metabolism measurements
Measurements were performed using a Seahorse Bioscience XF24 Extracellular Flux Data analysis was performed using the FlowJo software.
Superoxide anion production by the mitochondria
MitoSOX (Molecular Probes, Eugene, OR) was added to a final concentration of 5 μM for 10 min. After incubation, cells were washed with warm PBS, detached with Accutase, and resuspended in HBSS (Gibco, Life Technologies, Carlsbad, CA) for flow cytometry. 10,000
events per sample were collected in a MACSQuant-VYB, and data analysis was performed using FlowJo software.
Statistics
Statistical analyses were performed by using the unpaired 2-tailed Student t-test; either nonnormal distribution, 1-way ANOVA or 2-way ANOVA with Bonferroni post-hoc test were also used when appropriate. IC 50 and the area under the curve (AUC) values were calculated by non-linear regression curves with robust fit using GraphPad software. Values are expressed as mean ± SEM. Data are representative of at least three independent experiments with technical triplicates completed. P value less than 0.05 was considered significant.
Study approval
All experimental protocols were carried out in accordance with the nationally approved 
